-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875

Benzinga·11/02/2026 12:00:38
语音播报
Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.